☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Advertisement
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
AbbVie
AbbVie to Acquire Cerevel Therapeutics for ~$8.7B
December 7, 2023
AbbVie Enters into a Collaboration Agreement with BigHat Biosciences to Discover and Develop Therapeutic Antibodies
December 6, 2023
AbbVie to Acquire ImmunoGen for $10.1B
December 1, 2023
Abbvie Reports Positive Result for Telisotuzumab-Vedotin (Teliso-V) in P-II (LUMINOSITY) Study for the Treatment of NSCLC
November 30, 2023
AbbVie Publishes Results for Ubrelvy (ubrogepant) in P-III Trial for Migraine in ‘The Lancet’
November 17, 2023
AbbVie Reports Head-To-Head P-III Study (SEQUENCE) of Skyrizi (risankizumab) for Crohn's Disease
October 17, 2023
Load more...
Back to Home